Objectives: To evaluate efficacy and safety of an aflibercept treat-and-extend (TAE) regimen in patients with macular oedema (MO) secondary to central retinal vein occlusion (CRVO).

Design Setting And Patients: Phase IV, prospective, open-label, single-arm trial in 11 Spanish hospitals. Treatment-naïve patients with <6 month diagnosis of MO secondary to CRVO and best-corrected visual acuity (BCVA) of 73-24 ETDRS letters were included between 23 January 2015 and 17 March 2016.

Intervention: Intravitreal aflibercept 2 mg monthly (3 months) followed by proactive individualized dosing.

Main Outcomes: Mean change in BCVA after 12 months.

Results: 24 eyes (24 patients) were included; mean (SD) age: 62.8 (15.0) years; 54.2% male; median (IQR) time since diagnosis: 7.6 (3.0, 15.2) days. Mean BCVA scores significantly improved between baseline (56.0 (16.5)) and Month 12 (74.1 (17.6)); mean (95% CI) change: 14.8 (8.2, 21.4); =0.0001. Twelve (50.0%) patients gained ≥15 ETDRS letters. Foveal thickness improved between baseline (mean: 569.4 (216.8) m) and Month 12 (mean 257.4 (48.4) m); < 0.0001. At Month 12, 8.3% patients had MO. The mean (SD) number of injections: 8.3 (3.0). No treatment-related AEs were reported. Five (20.8%) patients experienced ocular AEs. Two nonocular serious AEs were reported.

Conclusions: An aflibercept TAE regimen improves visual acuity in patients with MO secondary to CRVO over 12 months with good tolerability.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204200PMC
http://dx.doi.org/10.1155/2018/8310350DOI Listing

Publication Analysis

Top Keywords

efficacy safety
8
safety aflibercept
8
aflibercept treat-and-extend
8
treatment-naïve patients
8
patients macular
8
macular oedema
8
oedema secondary
8
secondary central
8
central retinal
8
retinal vein
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!